Comparative Safety and Efficacy of Low-dose Vitamin D in Kidney Failure

小剂量维生素 D 治疗肾衰竭的安全性和疗效比较

基本信息

  • 批准号:
    10721791
  • 负责人:
  • 金额:
    $ 18.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-01 至 2028-04-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT The components of chronic kidney disease-mineral and bone disorder (CKD-MBD) include calcitriol deficiency, hyperphosphatemia, and excesses of fibroblast growth factor-23 (FGF-23) and parathyroid hormone (PTH), all of which consistently and strongly associate with cardiovascular disease (CVD) in patients with kidney failure on dialysis. Vascular calcifications are present in >80% of these patients and may be a mechanism through which CKD-MBD increases CVD risk. Intravenously-administered (IV) vitamin D receptor agonists (VDRA) are routinely used as first-line therapy for CKD-MBD in kidney failure, supported by experimental and epidemiological evidence that suggest VDRAs improve CVD and survival. However, the long-term risks and benefits of the current treatment approach, which encourages escalating VDRA doses to reduce PTH concentrations towards the normal range, have never been tested by clinical outcomes trials. This approach often leads to high VDRA doses which incur several risks: (1) a dose-dependent rise in FGF-23, a major risk factor for CVD that is associated with monotonically increasing risk of death in kidney failure; (2) hypercalcemia, a key promoter of vascular calcification; (3) low turnover bone disease, which drive calcium and phosphate into the vasculature because they cannot deposit into bone; (4) held doses of VDRA as a result of (2) and (3), which interrupts therapy and deprives patients of its likely health benefits. The goal of this project is to evaluate the safety, efficacy, and feasibility of a low fixed-dose vitamin D strategy to treat CKD-MBD in kidney failure to move the field towards identifying an optimal strategy that balances the risks and benefits of VDRA use. The two Aims proposed will leverage a unique partnership with Northwest Kidney Centers (NKC), the largest provider of dialysis in Seattle, WA. Aim 1 is a 12-month pragmatic randomized clinical trial of 90 NKC patients on hemodialysis that will compare the effects of a low fixed-dose oral calcitriol strategy (intervention) with the current usual care of PTH-titrated IV VDRAs (control) on a comprehensive panel of biomarkers assessing mineral metabolism, bone turnover, and serum calcification propensity, as well as measures of feasibility and acceptability. Aim 2 is a complementary retrospective cohort study using the NKC electronic health records database that will test associations between mean VDRA dose and variability in VDRA doses with CVD event and hospitalization rates. These Aims test whether a low fixed- dose vitamin D strategy has causal effects that improve intermediate outcomes (Aim 1) and associate with improved clinical outcomes (Aim 2), building a foundation for future large-scale clinical outcomes trials. Integrated with this research agenda is a career development plan designed to position me to become a successful independent investigator in the field of disordered mineral metabolism in CKD. This mentored approach to training includes regular meetings with co-mentors who are established leaders in multi- disciplinary fields, structured didactics, attendance at local and national conferences, and experiential training.
项目概要/摘要 慢性肾病-矿物质和骨骼疾病(CKD-MBD)的组成部分包括骨化三醇缺乏、 高磷血症以及成纤维细胞生长因子 23 (FGF-23) 和甲状旁腺激素 (PTH) 过量,所有这些 其中与肾衰竭患者的心血管疾病 (CVD) 始终密切相关 进行透析。超过 80% 的患者存在血管钙化,这可能是一种机制 CKD-MBD 会增加 CVD 风险。静脉注射 (IV) 维生素 D 受体激动剂 (VDRA) 是 常规用作肾衰竭 CKD-MBD 的一线治疗,并得到实验和研究的支持 流行病学证据表明 VDRAs 可以改善 CVD 和生存率。然而,长期风险和 当前治疗方法的好处,鼓励增加 VDRA 剂量以减少 PTH 浓度接近正常范围,从未经过临床结果试验测试。这种做法 通常会导致高 VDRA 剂量,从而引发多种风险:(1) FGF-23 剂量依赖性升高,这是一个主要风险 与肾衰竭死亡风险单调增加相关的 CVD 因素; (2) 高钙血症,血管钙化的关键促进因素; (3)低周转性骨病,导致钙的流失 磷酸盐进入脉管系统,因为它们不能沉积到骨骼中; (4) 因此持有 VDRA 剂量 (2) 和 (3),这会中断治疗并剥夺患者可能的健康益处。 该项目的目标是评估低固定剂量维生素 D 策略的安全性、有效性和可行性 治疗肾衰竭中的 CKD-MBD 推动该领域确定平衡的最佳策略 使用 VDRA 的风险和好处。拟议的两个目标将利用与西北航空的独特合作伙伴关系 肾脏中心 (NKC) 是华盛顿州西雅图最大的透析提供商。目标1是为期12个月的务实 对 90 名接受血液透析的 NKC 患者进行的随机临床试验,比较低固定剂量的效果 口服骨化三醇策略(干预)与目前 PTH 滴定 IV VDRAs 的常规护理(对照) 评估矿物质代谢、骨转换和血清钙化的综合生物标志物组 倾向以及可行性和可接受性的衡量标准。目标 2 是一个互补的回顾性队列 使用 NKC 电子健康记录数据库进行的研究将测试平均 VDRA 剂量之间的关联 VDRA 剂量随 CVD 事件和住院率的变化。这些目标测试是否低固定 维生素 D 剂量策略具有改善中间结果(目标 1)的因果效应,并与 改善临床结果(目标 2),为未来大规模临床结果试验奠定基础。 与该研究议程相结合的是一个职业发展计划,旨在使我成为一名 CKD 矿物质代谢紊乱领域的成功独立研究者。此次辅导的 培训方法包括与共同导师定期举行会议,这些导师是多领域公认的领导者 学科领域、结构化教学、参加地方和国家会议以及体验式培训。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Simon Hsu其他文献

Simon Hsu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Simon Hsu', 18)}}的其他基金

F32 Childcare Costs Supplement: Assessment of the Vitamin D Metabolite Ratio as a Therapeutic Target in Clinical Practice
F32 儿童保育费用补充:维生素 D 代谢物比率作为临床实践中治疗目标的评估
  • 批准号:
    10517816
  • 财政年份:
    2021
  • 资助金额:
    $ 18.77万
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 18.77万
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 18.77万
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 18.77万
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 18.77万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 18.77万
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 18.77万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 18.77万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 18.77万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 18.77万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 18.77万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了